Table 2: Overview of outcome of survey questionnaire
| Question | Timolol hemihydrate | Timolol in sorbate | p-value | ||||||||||
| N | Mean score | N | Mean score | ||||||||||
| 1. Burning/stinging? | 64 | 1.1 ± 1.1 | 39 | 2.4 ± 1.4 | <0.001 | ||||||||
| 2. Overall tolerability? | 64 | 0.8 ± 0.8 | 39 | 1.0 ± 0.9 | 0.28 | ||||||||
| 3. Overall comfort? | 64 | 0.8 ± 0.8 | 39 | 1.1 ± 1.0 | 0.14 | ||||||||
| 4. Tearing? | 64 | 0.9 ± 1.0 | 39 | 1.6 ± 1.6 | 0.024 | ||||||||
| 5. Light sensitivity? | 63 | 0.5 ± 0.7 | 38 | 0.4 ± 0.9 | 0.75 | ||||||||
| 6. Blurred vision? | 64 | 0.7 ± 1.0 | 39 | 0.6 ± 1.0 | 0.69 | ||||||||
| 7. Disruption of daily activities? | 63 | 0.1 ± 0.3 | 39 | 0.2 ± 0.5 | 0.53 | ||||||||
| 8. How long was disruption? | 11 | 0.2 ± 0.4 | 7 | 0.1 ± 0.4 | 0.84 | ||||||||
| 10. Overall comfort vs other glaucoma medicines? | 39 | 1.5 ± 0.9 | 26 | 1.6 ± 1.1 | 0.94 | ||||||||
| Question 9 | |||||||||||||
| response | Timolol hemihydrate | Timolol maleate in sorbate | Total | ||||||||||
| 1 | 5 | 5 | 10 | ||||||||||
| 2 | 2 | 0 | 2 | ||||||||||
| 6 | 2 | 1 | 3 | ||||||||||
| Total | 9 | 6 | 15 | ||||||||||
| p-value** | 0.41 | ||||||||||||
*2-tailed p-value, t-test; **Chi-square test